Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
|Videos|January 20, 2015
A Novel Anti-CXCR4 Antibody for Relapsed/Refractory Multiple Myeloma
Author(s)Irene Ghobrial, MD
Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.
Advertisement
Clinical Pearls
Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.
- This trial analyzed the anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide and low-dose dexamethasone, or with bortezomib plus dexamethasone in patients with relapsed or refractory multiple myeloma.
- Patients achieved a nearly 56% overall response rate.
- Many patients on the trial were refractory to lenalidomide.
More on this study > >
Advertisement
Related to this article
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
2
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
3
Pembrolizumab Plus SBRT Fails to Improve EFS in Unresected Early-Stage NSCLC
4
COA Backs 340B Payment Cut in 2027 Final Rules, Warns of Physician Cuts
5